Skip to Main Content

Paper Details

Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee.
Lancet Haematol
3
2023
Author NameAffiliation
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, USA Harvard Medical School, Harvard University
  • 1 - 1

Datasets

Release 1.2